The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Drafahl, Kristine A ^a   McAndrew, Christopher W ^a   Meyer, April N ^a   Haas, Martin ^b   Donoghue, Daniel J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR 4; I KAPPA B ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; FGF19 PROTEIN, HUMAN; FGFR4 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; GLUTATHIONE TRANSFERASE; I KAPPA B KINASE; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; IMMUNOPRECIPITATION; IN VITRO STUDY; MASS SPECTROMETRY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; ANIMAL; CELL PROLIFERATION; DNA MICROARRAY; HUMAN; INFLAMMATION; METABOLISM; MOUSE;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; FIBROBLAST GROWTH FACTORS; GLUTATHIONE TRANSFERASE; HUMANS; I-KAPPA B KINASE; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650984035     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014412     Document Type: Article

References (66)

1. Vojtek AB, Hollenberg SM, Cooper JA (1993) Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74: 205-214.
2. Schmid JA, Birbach A (2008) IkappaB kinase beta (IKKbeta/IKK2/IKBKB)- a key molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor Rev 19: 157-165.
3. Sarkar FH, Li Y (2008) NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci 13: 2950-2959.
4. Hacker H, Karin M (2006) Regulation and function of IKK and IKK-related kinases. Sci STKE 2006: re13.
5. Dutta J, Fan Y, Gupta N, Fan G, Gelinas C (2006) Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 25: 6800-6816.
6. Karin M (2008) The IkappaB kinase - a bridge between inflammation and cancer. Cell Res 18: 334-342.
7. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
8. Wang J, Yu W, Cai Y, Ren C, Ittmann MM (2008) Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 10: 847-856.
9. Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, et al. (2007) Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 213: 82-90.
10. Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, et al. (2005) Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 92: 320-327.
11. Huang J, Wu L, Tashiro S, Onodera S, Ikejima T (2006) Fibroblast growth factor-2 suppresses oridonin-induced L929 apoptosis through extracellular signal-regulated kinase-dependent and phosphatidylinositol 3-kinase-independent pathway. J Pharmacol Sci 102: 305-313.
12. Vandermoere F, El Yazidi-Belkoura I, Adriaenssens E, Lemoine J, Hondermarck H (2005) The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells. Oncogene 24: 5482-5491.
13. Gardner AM, Johnson GL (1996) Fibroblast growth factor-2 suppression of tumor necrosis factor alpha-mediated apoptosis requires Ras and the activation of mitogen-activated protein kinase. J Biol Chem 271: 14560-14566.
14. May MJ, Marienfeld RB, Ghosh S (2002) Characterization of the Ikappa Bkinase NEMO binding domain. J Biol Chem 277: 45992-46000.
15. Kwak YT, Guo J, Shen J, Gaynor RB (2000) Analysis of domains in the IKKalpha and IKKbeta proteins that regulate their kinase activity. J Biol Chem 275: 14752-14759.
16. Brill LM, Salomon AR, Ficarro SB, Mukherji M, Stettler-Gill M, et al. (2004) Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry. Anal Chem 76: 2763-2772.
17. Mukherji M, Brill LM, Ficarro SB, Hampton GM, Schultz PG (2006) A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways. Biochemistry 45: 15529-15540.
18. Shambharkar PB, Blonska M, Pappu BP, Li H, You Y, et al. (2007) Phosphorylation and ubiquitination of the IkappaB kinase complex by two distinct signaling pathways. Embo J 26: 1794-1805.
19. Schomer-Miller B, Higashimoto T, Lee YK, Zandi E (2006) Regulation of IkappaB kinase (IKK) complex by IKKgamma-dependent phosphorylation of the T-loop and C terminus of IKKbeta. J Biol Chem 281: 15268-15276.
20. Zandi E, Chen Y, Karin M (1998) Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science 281: 1360-1363.
21. Delhase M, Hayakawa M, Chen Y, Karin M (1999) Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science 284: 309-313.
22. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, et al. (2000) Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19: 3309-3320.
23. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M (1997) The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 91: 243-252.
24. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M (1997) A cytokine-responsive IkappaB kinase that activates the transcription factor NFkappaB. Nature 388: 548-554.
25. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S (1995) Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 9: 2723-2735.
26. Baeuerle PA, Baltimore D (1996) NF-kappa B: ten years after. Cell 87: 13-20. 27. Baldwin AS, Jr. (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683.
27. Xie MH, Holcomb I, Deuel B, Dowd P, Huang A, et al. (1999) FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 11: 729-735.
28. Chandler LA, Sosnowski BA, Greenlees L, Aukerman SL, Baird A, et al. (1999) Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines. Int J Cancer 81: 451-458.
29. Taghiyev AF, Guseva NV, Sturm MT, Rokhlin OW, Cohen MB (2005) Trichostatin A (TSA) sensitizes the human prostatic cancer cell line DU145 to death receptor ligands treatment. Cancer Biol Ther 4: 382-390.
30. Rokhlin OW, Glover RA, Taghiyev AF, Guseva NV, Seftor RE, et al. (2002) Bisindolylmaleimide IX facilitates tumor necrosis factor receptor familymediated cell death and acts as an inhibitor of transcription. J Biol Chem 277: 33213-33219.
31. Cai T, Nishida K, Hirano T, Khavari PA (2002) Gab1 and SHP-2 promote Ras/MAPK regulation of epidermal growth and differentiation. J Cell Biol 159: 103-112.
32. Baek K, Brown RS, Birrane G, Ladias JA (2007) Crystal structure of human cyclin K, a positive regulator of cyclin-dependent kinase 9. J Mol Biol 366: 563-573.
33. Mann DJ, Child ES, Swanton C, Laman H, Jones N (1999) Modulation of p27(Kip1) levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. Embo J 18: 654-663.
34. Besson A, Dowdy SF, Roberts JM (2008) CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14: 159-169.
35. Winkler GS (2010) The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol 222: 66-72.
36. Noels H, Bernhagen J, Weber C (2009) Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis. Trends Cardiovasc Med 19: 76-86.
37. Chaudhari BR, Murphy RF, Agrawal DK (2006) Following the TRAIL to apoptosis. Immunol Res 35: 249-262.
38. Wilson NS, Dixit V, Ashkenazi A (2009) Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol 10: 348-355.
39. Lamarca V, Sanz-Clemente A, Perez-Pe R, Martinez-Lorenzo MJ, Halaihel N, et al. (2007) Two isoforms of PSAP/MTCH1 share two proapoptotic domains and multiple internal signals for import into the mitochondrial outer membrane. Am J Physiol Cell Physiol 293: C1347-1361.
40. Ong SH, Hadari YR, Gotoh N, Guy GR, Schlessinger J, et al. (2001) Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci U S A 98: 6074-6079.
41. Meyer AN, Gastwirt RF, Schlaepfer DD, Donoghue DJ (2004) The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation. J Biol Chem 279: 28450-28457.
42. Kang S, Dong S, Gu TL, Guo A, Cohen MS, et al. (2007) FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12: 201-214.
43. Kong M, Wang CS, Donoghue DJ (2002) Interaction of fibroblast growth factor receptor 3 and the adapter protein SH2-B. A role in STAT5 activation. J Biol Chem 277: 15962-15970.
44. Sun L, Carpenter G (1998) Epidermal growth factor activation of NF-kappaB is mediated through IkappaBalpha degradation and intracellular free calcium. Oncogene 16: 2095-2102.
45. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB (2007) Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinaseindependent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene 26: 7324-7332.
46. Biswas DK, Cruz AP, Gansberger E, Pardee AB (2000) Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A 97: 8542-8547.
47. Guo G, Wang T, Gao Q, Tamae D, Wong P, et al. (2004) Expression of ErbB2 enhances radiation-induced NF-kappaB activation. Oncogene 23: 535-545.
48. Koumakpayi IH, Le Page C, Mes-Masson AM, Saad F (2010) Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/ NF-kappaB signalling pathway and prognostic significance in prostate cancer. Br J Cancer 102: 1163-1173.
49. Woodworth CD, Michael E, Marker D, Allen S, Smith L, et al. (2005) Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther 4: 650-658.
50. Nikolaidis NM, Gray JK, Gurusamy D, Fox W, Stuart WD, et al. (2010) Ron receptor tyrosine kinase negatively regulates TNFalpha production in alveolar macrophages by inhibiting NF-kappaB activity and Adam17 production. Shock 33: 197-204.
51. Stark KL, McMahon JA, McMahon AP (1991) FGFR-4, a new member of the fibroblast growth factor receptor family, expressed in the definitive endoderm and skeletal muscle lineages of the mouse. Development 113: 641-651.
52. Korhonen J, Partanen J, Alitalo K (1992) Expression of FGFR-4 mRNA in developing mouse tissues. Int J Dev Biol 36: 323-329.
53. Ho HK, Pok S, Streit S, Ruhe JE, Hart S, et al. (2009) Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 50: 118-127.
54. Desnoyers LR, Pai R, Ferrando RE, Hotzel K, Le T, et al. (2008) Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 27: 85-97.
55. Murphy T, Darby S, Mathers ME, Gnanapragasam VJ (2010) Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J Pathol 220: 452-460.
56. Taylor JGT, Cheuk AT, Tsang PS, Chung JY, Song YK, et al. (2009) Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest 119: 3395-3407.
57. Roidl A, Foo P, Wong W, Mann C, Bechtold S, et al. (2009) The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene.
58. Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P, et al. (2009) Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 upregulation. Clin Cancer Res 15: 2058-2066.
59. Pai R, Dunlap D, Qing J, Mohtashemi I, Hotzel K, et al. (2008) Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res 68: 5086-5095.
60. St Bernard R, Zheng L, Liu W, Winer D, Asa SL, et al. (2005) Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 146: 1145-1153.
61. Meyer AN, McAndrew CW, Donoghue DJ (2008) Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells. Cancer Res 68: 7362-7370.
62. Kong M, Barnes EA, Ollendorff V, Donoghue DJ (2000) Cyclin F regulates the nuclear localization of cyclin B1 through a cyclin-cyclin interaction. Embo J 19: 1378-1388.
63. McAndrew CW, Gastwirt RF, Meyer AN, Porter LA, Donoghue DJ (2007) Spy1 enhances phosphorylation and degradation of the cell cycle inhibitor p27. Cell Cycle 6: 1937-1945.
64. Robertson SC, Meyer AN, Hart KC, Galvin BD, Webster MK, et al. (1998) Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain. Proc Natl Acad Sci U S A 95: 4567-4572.
65. O'Dea EL, Barken D, Peralta RQ, Tran KT, Werner SL, et al. (2007) A homeostatic model of IkappaB metabolism to control constitutive NF-kappaB activity. Mol Syst Biol 3: 111.
66. Hoffmann A, Levchenko A, Scott ML, Baltimore D (2002) The IkappaB-NFkappaB signaling module: temporal control and selective gene activation. Science 298: 1241-1245.